Treating cardiovascular disease in women

Menopause International

Volumn 13, Issue 4, 2007, Pages 159-164

  Taggu, Wasing ^a   Lloyd, Guy ^a  

^a EASTBOURNE DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Coronary artery bypass grafting; Coronary heart disease; Ischaemic heart disease; Women's health

Indexed keywords

CARDIOVASCULAR AGENT; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EZETIMIBE; FENOFIBRATE; FIBRINOLYTIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PRAVASTATIN; SERUM AMYLOID A; SEX HORMONE; SIMVASTATIN;

ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DYSLIPIDEMIA; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; LIFESTYLE; MENTAL STRESS; OBESITY; ORGANIZATION AND MANAGEMENT; POSTMENOPAUSE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; UNITED STATES; WOMEN'S HEALTH; ATHERECTOMY; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT LYSIS; BODY MASS; BRACHYTHERAPY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY STENT; DISEASE PREDISPOSITION; DRUG SAFETY; EXERCISE; FAMILY HISTORY; GRAFT FAILURE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HORMONE SUBSTITUTION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MENOPAUSE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RISK REDUCTION; SECONDARY PREVENTION; SITTING; STABLE ANGINA PECTORIS; STROKE; SURVIVAL RATE; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY ARTERY BYPASS; DYSLIPIDEMIAS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEART CATHETERIZATION; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; POSTMENOPAUSE; PRIMARY PREVENTION; RISK FACTORS; SEX FACTORS; SMOKING; STRESS, PSYCHOLOGICAL; UNITED STATES; WOMEN'S HEALTH;

EID: 41949105748     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507783004104     Document Type: Review

References (63)

1. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006;27:994–1005.
2. British Heart Foundation. See http://www.heartstats.org, last accessed August 2007.
3. Vasan RS, Sullivan LM, Wilson PW, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005;142:393–402.
4. Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. J Intern Med 2007;262:145–56.
5. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in the Framingham population. Sixteen year follow-up. Diabetes 1974;23:105–11.
6. Yusaf S, Hawken S, Ounpuu S, et al., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study. Lancet 2004;364:937–52.
7. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow up. Arch Intern Med 2001;161: 1717–23.
8. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study on 13,000 men and women with 20 years follow-up. Arch Intern Med 2004; 164:1422–6.
9. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971–2000. Ann Intern Med 2007; Epub ahead of print.
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002;106;3143–421.
11. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32–47.
12. Department of Health. National Service Framework for Coronary Heart Disease. London: DH, 2000.
13. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 (Suppl 5):v1–52.
14. Department of Health. Health Survey for England. The Health of Ethnic Minority Groups 1999. London: The Stationery Office, 2001.
15. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995;76:69C–77C.
16. Johansson S, Wilhelmsen L, Lappas G, Rosengren A. High lipid levels and coronary disease in women in Goteborg – outcome and secular trends: a prospective 19 year follow-up in the BEDA*study. Eur Heart J 2003;24:704–16.
17. Legato MJ. Dyslipidaemia, gender, and the role of high density lipoprotein cholesterol: implications for therapy. Am J Cardiol 2000;86:15L–18L.
18. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681–9.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
20. Manson JE, Willet WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995;333:677–85.
21. Yarnell JW, Patterson CC, Thomas HF, et al. Central obesity: predictive value of skinfold measurements for subsequent ischaemic heart disease at 14 years follow-up in the Caerphilly Study. Int J Obes Relat Metab Disord 2001;25:1546–9.
22. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
23. Scottish Health Survey. See www.scotland.gov.uk, last accessed July 2007.
24. Van der Giezen AM, Schopman-Geurts van Kessel JG, Schouten EG, et al. Systolic blood pressure and cardiovascular mortality among 13,740 Dutch women. Prev Med 1990;19:456–65.
25. National Heart, Lung, and Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure – Complete Report, 2004.
26. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519–27.
27. Allender S, Peto V, Scarborough P, Boxer A, Rayner M. Coronary Heart Disease Statistics. London: British Health Foundation, 2007.
28. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002.
29. Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all cause mortality: a prospective study of healthy men and women. JAMA 1989;262:2395–401.
30. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins and coronary heart disease in women. Clin Chem 1988;34: B60–70.
31. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999;341:650– 8.
32. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: 26-year follow-up of the Framingham population. Am Heart J 1986;111:383–90.
33. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12.
34. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77.
35. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81– 106.
36. Lonn E, Roccaforte R, Yi Q, et al.; HOPE Investigators. Heart Outcomes Prevention Evaluation. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002;40:693–702.
37. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–6.
38. Malenka DJ, O' Rourke D, Miller MA, et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group. Am Heart J 1999;137: 632–8.
39. Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous transluminal coronary angioplasty in women. 1985–1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993;87:720–7.
40. O'Connor GT, Malenka DJ, Quinton H, et al. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994–1996. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999;34: 681–91.
41. Keelan ET, Nunez BD, Grill DE, et al. Comparison of immediate and long-term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women. Mayo Clin Proc 1997;72:5–12.
42. Vakili BA, Kaplan RC, Brown DL. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001;104:3034–8.
43. Edwards FH, Carey JS, Grover FL, Bero JW, Hartz RS. Impact of gender on coronary bypass operative mortality. Ann Thorac Surg 1998;66:125–31.
44. Jacobs AK. Coronary revascularization in women in 2003. Sex revisited. Circulation 2003;107:375.
45. Ades PA, Waldmann ML, Polk DM, et al. Referral patterns and exercise responses in the rehabilitation of female coronary patients aged greater than 62. Am J Cardiol 1992;69:1422–5.
46. Peterson ED, Alexander KP. Learning to suspect the unexpected: evaluating women with cardiac syndromes. Am Heart J 1998; 136:186–8.
47. Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med 2004;116:693–706.
48. Antman EM, Anbe DT, Armstrong PW, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2004;110:588–636.
49. Moen EK, Asher CR, Miller DP, et al. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. J Women's Health 1997;6:285–93.
50. Lagerqvist B, Safstrom K, Stahle E, et al.; FRISC II Study Group Investigators. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? J Am Coll Cardiol 2001;38:41–8.
51. Fox KA, Poole-Wilson PA, Henderson RA, et al. Randomized Intervention Trial of unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA-3 randomised trial. Lancet 2002;360:743–51.
52. Woodfield SL, Lundergan CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol 1997;29:35–42.
53. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; ii:57–66.
54. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction – I. Arch Intern Med 1998;158:981–8.
55. Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 2000;343:8–15.
56. Stone GW, Grines CL, Browne KF, et al. A comparison of inhospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 1995;75:987–92.
57. Wong SC, Sleeper LA, Monrad ES, et al., for the SHOCK investigators. Absence of gender differences in clinical outcomes in patient with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK trial registry. J Am Coll Cardiol 2001;38:1395–401.
58. Fetters JK, Peterson ED, Shaw LJ, et al. Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? Am Heart J 1996;131:796–813.
59. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521–7.
60. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1994;90:2645–57.
61. Mosca L, Appel LJ, Benjamin EJ, et al.; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672–93.
62. Thom TJ, Kannel WB, Silbershatz S, et al. Incidence, prevalence, and mortality of cardiovascular diseases in the United States. In: Alexander RW, ed. Hurst's The Heart (9th edn). New York: McGraw-Hill, 1998: 3.
63. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189–98.